Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 12, 2016 - Issue 5
Submit an article Journal homepage
755
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Therapy implications for the role of IL-21 in lupus

Vincenzo DinalloDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyView further author information
,
Davide Di FuscoDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyView further author information
,
Roberta IzzoDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyView further author information
&
Giovanni MonteleoneDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyCorrespondence[email protected]
View further author information
Pages 487-488 | Received 29 Dec 2015, Accepted 05 Feb 2016, Published online: 24 Feb 2016

References

  • Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878–1888.
  • Sarra M, Monteleone G. Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:294582.
  • Sawalha AH, Kaufman KM, Kelly JA, et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis. 2008;67:458–461.
  • Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–2121.
  • Davis LS, Hutcheson J, Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31:781–789.
  • Di Fusco D, Izzo R, Figliuzzi MM, et al. IL-21 as a therapeutic target in inflammatory disorders. Expert Opin Ther Targets. 2014;18:1329–1338.
  • Webb R, Merrill JT, Kelly JA, et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum. 2009;60:2402–2407.
  • Lan Y, Luo B, Wang J-L, et al. The association of interleukin-21 polymorphisms with interleukin-21 serum levels and risk of systemic lupus erythematosus. Gene. 2014;538:94–98.
  • Caruso R, Botti E, Sarra M, et al.. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med. 2009;15:1013–1015.
  • Yin S, Mao Y, Li X, et al. Hyperactivation and in situ recruitment of inflammatory Vδ2 T cells contributes to disease pathogenesis in systemic lupus erythematosus. Sci Rep. 2015;5:14432.
  • Terrier B, Costedoat-Chalumeau N, Garrido M, et al. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol. 2012;39:1819–1828.
  • Lee J, Shin E-K, Lee S-Y, et al. Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus. Immunology. 2014;142:573–580.
  • Izui S, Ibnou-Zekri N, Fossati-Jimack L, et al. Lessons from BXSB and related mouse models. Int Rev Immunol. 2000;19:447–472.
  • Bubier JA, Bennett SM, Sproule TJ, et al. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1110:590–601.
  • Bubier JA, Sproule TJ, Foreman O, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A. 2009;106:1518–1523.
  • Herber D, Brown TP, Liang S, et al. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol. 2007;178:3822–3830.
  • Linterman MA, Rigby RJ, Wong RK, et al. Follicular helper T cells are required for systemic autoimmunity. J Exp Med. 2009;206:561–576.
  • Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014;13:379–395.
  • Hua F, Comer GM, Stockert L, et al. Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014;54:14–22.
  • McPhee CG, Bubier JA, Sproule TJ, et al. IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB.Yaa mice. J Immunol. 2013;191:4581–4588.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.